Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) Price Target at $11.71

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have received a consensus rating of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $11.79.

A number of brokerages have recently commented on HCAT. Stephens boosted their price target on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Royal Bank of Canada boosted their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Evercore ISI boosted their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Citigroup lifted their target price on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. lifted their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th.

Health Catalyst Stock Performance

HCAT stock opened at $8.65 on Monday. The business’s 50-day moving average price is $8.13 and its two-hundred day moving average price is $7.30. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market cap of $526.34 million, a PE ratio of -6.41 and a beta of 1.32. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. As a group, research analysts forecast that Health Catalyst will post -0.35 earnings per share for the current year.

Insider Activity

In other news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total value of $40,109.30. Following the transaction, the chief operating officer now owns 129,690 shares of the company’s stock, valued at approximately $998,613. This represents a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 34,068 shares of company stock valued at $257,555. 2.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC grew its position in Health Catalyst by 438.5% during the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after buying an additional 3,221,408 shares in the last quarter. Impax Asset Management Group plc grew its position in Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after buying an additional 360,201 shares in the last quarter. Millennium Management LLC grew its position in Health Catalyst by 96.3% during the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after buying an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA grew its position in Health Catalyst by 1.1% during the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after buying an additional 25,000 shares in the last quarter. Finally, Daventry Group LP grew its position in Health Catalyst by 3.9% during the second quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after buying an additional 84,178 shares in the last quarter. 85.00% of the stock is owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.